DNA甲基化谱预测脑膜瘤复发风险:列线图的开发与验证
研究利用多机构临床注释肿瘤样本的DNA甲基化谱,开发了5年无复发生存(RFS)的甲基化模型,并整合临床因素构建列线图。甲基化预测因子优于基于分级的预测因子,列线图区分度高于仅临床因素模型,可个体化指导术后辅助放疗决策。
要点
- 甲基化模型预测5年RFS优于分级模型(ΔAUC=0.10)。
- 列线图整合甲基化与临床因素,区分度优于临床模型(ΔAUC=0.25)。
- 模型可帮助个体化决定术后是否行辅助放疗。
核心结论
- DNA甲基化模型联合临床因素的列线图可提供现有临床和分子因素未捕获的预后信息,有助于个体化术后治疗决策。
研究设计与样本
- 利用多机构临床注释肿瘤样本的DNA甲基化谱开发5年RFS甲基化模型,并构建整合甲基化模型与预后临床因素的列线图,在多个独立队列中验证和比较。
主要发现
- 甲基化预测因子在3个验证队列中优于基于分级的预测因子(ΔAUC=0.10,95%CI:0.03-0.018)。
- 调整组织病理分级、切除范围和拷贝数改变负担后,甲基化预测因子仍独立关联RFS(HR=3.6,95%CI:1.8-7.2,P<0.001)。
- 列线图在2个独立验证队列中区分度优于仅临床因素列线图(ΔAUC=0.25,95%CI:0.22-0.27),并分出两种复发模式不同的组(HR=7.7,95%CI:5.3-11.1,P<0.001)。
临床怎么用
- 可将甲基化模型与临床因素结合的列线图用于脑膜瘤术后复发风险个体化评估,辅助选择辅助放疗或观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection of patients who would benefit from adjuvant radiotherapy to delay recurrence. We aimed to develop an individualized prediction model of early recurrence risk combining clinical and molecular factors in meningioma. METHODS: DNA methylation profiles of clinically annotated tumor samples across multiple institutions were used to develop a methylome model of 5-year recurrence-free survival (RFS). Subsequently, a 5-year meningioma recurrence score was generated using a nomogram that integrated the methylome model with established prognostic clinical factors. Performance of both models was evaluated and compared with standard-of-care models using multiple independent cohorts. RESULTS: The methylome-based predictor of 5-year RFS performed favorably compared with a grade-based predictor when tested using the 3 validation cohorts (ΔAUC = 0.10, 95% CI: 0.03-0.018) and was independently associated with RFS after adjusting for histopathologic grade, extent of resection, and burden of copy number alterations (hazard ratio 3.6, 95% CI: 1.8-7.2, P < 0.001). A nomogram combining the methylome predictor with clinical factors demonstrated greater discrimination than a nomogram using clinical factors alone in 2 independent validation cohorts (ΔAUC = 0.25, 95% CI: 0.22-0.27) and resulted in 2 groups with distinct recurrence patterns (hazard ratio 7.7, 95% CI: 5.3-11.1, P < 0.001) with clinical implications. CONCLUSIONS: The models developed and validated in this study provide important prognostic information not captured by previously established clinical and molecular factors which could be used to individualize decisions regarding postoperative therapeutic interventions, in particular whether to treat patients with adjuvant radiotherapy versus observation alone.
引用
- Nassiri F, Mamatjan Y, Suppiah S, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 2019. PMID: 31158293. doi:10.1093/neuonc/noz061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。